Stay updated on LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.

Latest updates to the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page now shows a new revision label (v3.5.3), replacing the previous v3.5.2 to indicate a fresh revision of the page content.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0, updating the page’s version information.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedA newer revision, v3.5.0, was added and the older revision, v3.4.3, was removed.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision updated to v3.4.3, replacing the previous v3.4.2 reference.SummaryDifference0.1%

- Check86 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-status notice (Revision: v3.4.1). These are minor page-level updates that do not affect study data or user actions.SummaryDifference0.4%

- Check93 days agoChange DetectedAdded a government funding notice banner and updated the page version to v3.4.1 (removing v3.4.0). The changes appear cosmetic and do not modify the study details, eligibility criteria, or outcomes.SummaryDifference0.4%

Stay in the know with updates to LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.